 - Patients with an active infection or with a fever 38.5oC within 3 days of the first scheduled day of dosing; patients who are registered but develop a fever of 38.5oC may remain in the study if the fever abates prior to the expiration of the screening procedures; if the screening procedures have expired, the patient may be re-screened once afebrile 